Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LeMaitre VascularLMAT +0.78%100 EV-to-OCF is 19.21 as of Aug. 07, 2026, which is 38% below its 10-year median of 31.20. GuruFocus rates LMAT with a GF Score™ of 100/100 and a GF Value™ of $95.26 (Modestly Undervalued). Among 852 Medical Devices & Instruments companies, LeMaitre Vascular ranks worse than 76.17% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, LeMaitre Vascular's Enterprise Value is $1,676.7 Mil.
LeMaitre Vascular's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $87.3 Mil. Therefore, LeMaitre Vascular's EV-to-OCF for today is 19.21.
The historical rank and industry rank for LeMaitre Vascular's EV-to-OCF or its related term are showing as below:
LMAT'
s EV-to-OCF Range Over the Past 10 Years
Min: 19.66 Med: 31.2 Max: 63.4
Current: 20.21
During the past 13 years, the highest EV-to-OCF of LeMaitre Vascular was 63.40. The lowest was 19.66. And the median was 31.20.
LMAT's EV-to-OCF is ranked worse than 76.17% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 7.835
vs LMAT: 20.21
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
LeMaitre Vascular's PE Ratio (TTM) for today is calculated as:
LeMaitre Vascular's share price for today is $81.45.
LeMaitre Vascular's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.850.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
LeMaitre Vascular EV-to-OCF Related Terms
LeMaitre Vascular EV-to-OCF Historical Data
* Premium members only.
The historical data trend for LeMaitre Vascular's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, LeMaitre Vascular's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LeMaitre Vascular EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, LeMaitre Vascular's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where LeMaitre Vascular's EV-to-OCF falls into.
LeMaitre Vascular's current Enterprise Value is $1,676.7 Mil.
LeMaitre Vascular's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $87.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LeMaitre Vascular (LMAT) has a EV-to-OCF of 19.21 as of Aug. 07, 2026. This is 38% below median its historical median of 31.20. Over the past decade, LeMaitre Vascular's EV-to-OCF has ranged from 19.66 to 63.40. According to the industry distribution chart, LeMaitre Vascular ranks #649 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 76.2%.
Is LeMaitre Vascular's EV-to-OCF too high?
LeMaitre Vascular's current EV-to-OCF of 19.21 is 38% below median its 10-year median of 31.20. Over the past 10 years, this metric has ranged from a low of 19.66 to a high of 63.40. The Medical Devices & Instruments industry median EV-to-OCF is 7.84. LeMaitre Vascular's value of 19.21 is 145.2% above this industry median. Based on the distribution chart, LeMaitre Vascular ranks #649 out of 852 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, LeMaitre Vascular has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does LeMaitre Vascular's EV-to-OCF compare to PLSE and XRAY?
According to the Medical Devices & Instruments industry distribution chart, LeMaitre Vascular ranks #649 out of 852 companies for EV-to-OCF. This places LeMaitre Vascular in the lower half of its industry. The industry median EV-to-OCF is 7.84. LeMaitre Vascular's value of 19.21 is 145.2% above this benchmark. Historically, LeMaitre Vascular's own EV-to-OCF has ranged from 19.66 to 63.40 over the past decade. While the company's 10-year median is 31.20 vs. the industry median of 7.84, LeMaitre Vascular has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.84, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LeMaitre Vascular's current EV-to-OCF of 19.21 is 145.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LeMaitre Vascular's current EV-to-OCF is 19.21, which is 38% below median its own 10-year median of 31.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LeMaitre Vascular stock overvalued right now?
Based on GuruFocus' analysis, LeMaitre Vascular (LMAT) is currently considered Modestly Undervalued. The stock's GF Value™ is $95.26, compared to a current price of $81.45 — trading 14.5% below its estimated fair value. The current EV-to-OCF is 19.21, which is 38% below median its 10-year median of 31.20 and 145.2% above the Medical Devices & Instruments industry median of 7.84. LeMaitre Vascular's overall GF Score™ is 100/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For LeMaitre Vascular (LMAT), the current EV-to-OCF is 19.21 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LeMaitre Vascular (LMAT) Overvalued in 2026?
Based on GuruFocus' analysis, LeMaitre Vascular stock appears to be undervalued.
The current stock price of $81.45 is trading 14.5% below its estimated GF Value™ of $95.26.
GuruFocus considers LeMaitre Vascular to be Modestly Undervalued.
Key valuation signals for LMAT:
EV-to-OCF: 19.21 (38% below median its 10-year median of 31.20)
GF Value™: $95.26 vs. price of $81.45 (14.5% below fair value)
Industry Position: 145.2% above the Medical Devices & Instruments median (#649 of 852)
No single metric tells the full story. See the LMAT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
100GF Score
Get the complete analysis for LMAT
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LMAT has been successfully added to your 
